Award
National Institute of Allergy and Infectious Diseases 5R01AI176834-03
In vivo assessment and optimization of phage PK/PD for the treatment of pulmonary Mycobacterium abscessus infection
Recipient
Colorado State University
Award Amount
$782,871.00
Ceiling
$782,871.00
Awarded
December 29, 2025
Identifier
5R01AI176834-03
NIH awarded $782,871 to Colorado State University for research on optimizing phage therapy pharmacokinetics and pharmacodynamics to treat pulmonary Mycobacterium abscessus infection, aiming to develop models for clinical translation.
Description
This project aims to investigate the use of bacteriophage to treat Mycobacterium abscessus (Mabs) infection. Using a preclinical mouse lung infection model, the study will perform in vivo pharmacokinetics (PK) and pharmacodynamics (PD) studies of phage therapy. The research will evaluate different delivery routes (intravenous and intratracheal), liposome-encapsulated phage, and combination with antibiotics to optimize phage dosing strategies. The goal is to develop a quantitative systems pharmacology (QSP) model to facilitate clinical translation of phage therapy for Mabs.